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Background: Increased metastasis has been proved to be associated with a poor prognosis for hepatocellular
carcinoma (HCC). There are higher-level expressions of integrin α6 in the tissues of HCC patients with a higher
fatality rate. The aim of this study is to investigate the effect of short hairpin RNA (shRNA) silencing integrin α6
expression on the proliferation and metastasis in HCC cell lines.
Methods: Two human HCC cell lines, HepG2 and Bel-7402 were transfected with shRNA targeting human integrin
α6. Protein and mRNA expression level were determined by western blot and real-time quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) to detect the transfected efficacy. The metastasis potential of
HCC cells was evaluated by their proliferation, adhesion and invasion abilities. Cell proliferation was measured by
MTT assay. Adhesion ability was measured by adhesion and spreading assays. The expression of matrix metallopro-
teinases (MMPs) was measured by qRT-PCR. The potential of invasion was measured by qRT-PCR and Transwell
chamber assay. PI3K inhibitor LY294002 was used to explore the signal pathways of integrin α6 in HCC cells.
Results: Western blot and qRT-PCR detection showed that over 75% of integrin α6 expression in HCC cells was
through knockdown by shRNA. Proliferation, adhesion, spreading and invasion of HepG2 and Bel-7402 cells were
dramatically decreased in cells transfected with shRNA compared to the control cells. P-ERK and p-AKT were
reduced by shRNA targeting integrin α6 and PI3K inhibitor LY294002.
Conclusion: Knockdown integrin α6 can inhibit the proliferation and metastasis of HCC cells through PI3K/ARK and
MAPK/ERK signal pathways by shRNA in vitro. Integrin α6 can mediate the metastasis potential, and can be used as
a candidate target for therapy in HCC resulting in improved patients’ survival.
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Hepatocellular carcinoma (HCC) is a highly lethal can-
cer with a poor prognosis. The occurrence of HCC has
recently shown a worldwide increase [1], mainly because
of its high metastasis potential [2].
Integrins are heterodimeric transmembrane receptors
composed of non-covalently associated α and β subunits.
At least 18 α and 8 β subunits have been identified so
far, generating more than 24 members of the integrin
family. Increasing evidence suggests that integrins are* Correspondence: jikungwang@hotmail.com
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stated.the most important receptors for cell metastasis [3]. Re-
cently, it has been reported in many researches that in-
tegrin α6β1 and α6β4 were associated with metastasis of
HCC [4,5] and patients with high levels of expression of
integrin α6β1 have a poorer prognosis [4,6]. Higher
levels of expression of integrin α6β4 in patients is associ-
ated with increased invasive potential of HCC, as well as
a higher fatality rate [5,7]. Integrin α6β1, as an important
kind of cell surface receptor, can mediate the adhesion
between HCC cells and extracellular matrix (ECM) [8,9].
Owens et al. [10] demonstrates that integrin α6β4 could
regulate the migration and invasion of laminin (LN) to
stimulate the metastasis potential of HCC.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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gle action of integrin α6 alone in the progression of
HCC metastasis. Furthermore, the metastatic mecha-
nisms under high levels of expression of integrin α6 are
still unclear. A better understanding of the molecular
mechanisms underlying integrin α6 affecting HCC me-
tastasis may facilitate the development of targeted
therapy.
In the current study, in order to explore the effect of
integrin α6 in the process of HCC metastasis without
the influence of β subunits and the molecular mecha-
nisms involved, two human HCC cell line, HepG2 and
Bel-7402 were transfected with short hairpin RNA
(shRNA) targeting human integrin α6. The metastasis
potential of HCC cells was evaluated by proliferation,
adhesion and invasion abilities. PI3K inhibitor LY294002
was also used to explore the signal pathway of integrin
α6 in HCC cells.Methods
Cell culture and plasmids preparation
Two hepatocellular cell lines, HepG2 and Bel-7402 were
purchased from the Chinese Academy of Medical Sci-
ence (Beijing, China). All cells were cultured in RPMI
1640 (Life Technologies Corporation, 5791 Van Allen
Way, Carlsbad, CA 92008, US) with 10% FBS, 200 μg/ml
penicillin and streptomycin at 37°C in 5% CO2. Integrin
α6 shRNA plasmids (sc-43129-sh) were constructed and
synthesized by Santa Cruz Biotechnology, Inc., CA,
USA. Plasmids containing puromycin resistance genes
were used for the selection of cells stably expressing
shRNA. Control shRNA plasmids (sc-108065), each en-
coding a scrambled shRNA sequence that will not lead
to the specific degradation of any known cellular mRNA,
were also purchased from Santa Cruz Biotechnology,
Inc., CA, USA.Cell transfection and clone selection
Integrin α6 shRNA plasmids or control shRNA plasmids
were transfected into HepG2 and Bel-7402 cells respect-
ively, according to the manufacturer's instructions with
slight modification. Briefly, in a 24-well tissue culture
plate, cells were grown to approaching up to 85% to 90%
confluence in RPMI 1640 with 10% FBS. The medium
was aspirated 24 hours before transfection, and replaced
with DMEM. Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) 0.5 μl and plasmids 0.02 μg were added in
each well and incubated for six hours. After that, cells
were cultured in RPMI 1640 with 20% FBS, 400 μg/ml
penicillin and streptomycin for 18 hours. After replacing
the media with fresh normal growth medium, cells were
incubated for an additional 24 hours. Three days later,
stable transfectant clones were isolated with 1.6 μg/mland 2 μg/ml puromycin (Santa Cruz Biotechnology, Inc.,
CA, USA) in HepG2 and Bel-7402 respectively.
RNA extraction and qRT-PCR assays
Briefly, 2 μg total RNA was used to synthesize first-
strand cDNA. Amplification and detection were per-
formed using the ABI Prism 7500 Fast Real-time System
(Applied Biosystems, Foster City, California, USA) start-
ing with 1 μl cDNA and TransStart Top Green qPCR
SuperMix (TransGen Biotech, Beijing, China). Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was used
as internal standard.
Primers sequences for integrin α6, matrix metallopro-
teinase (MMP)-2, MMP-9 and GAPDH were as follows:








The relative expression of integrin α6, MMP-2 and
MMP-9 mRNA was analyzed by the comparative cycle
threshold (Ct) method. All experiments were performed
in triplicate.
Western blot assays
Cells (1 × 106) were washed with PBS twice and lysed
with 1 ml RIPA lysis buffer supplemented with
40 mmol/L NaF, 100 μmol/L Na3VO4, and 1 μl
Complete Protease Inhibitor (KeyGen Biotech Co. Ltd,
Nanjing, China) for 30 minutes on ice. After removing
the insoluble material by 12,000 × g centrifugation for
30 minutes at 4°C, the supernatants were collected,
boiled in 1 × sodium dodecyl sulfate sample buffer for
five minutes. Subsequent immunoblots were probed
with the appropriate antibody and detected by Gel Im-
aging System G: BOX (Gene Company Limited, Cam-
bridge, UK). Monoclonal rabbit anti-human CD49f
(1:100, Abgent, San Diego, CA, USA), rabbit anti-human
AKT (1:200); rabbit anti-human p-AKT (1:200); rabbit
anti-human ERK (1:200); and rabbit anti-human p-ERK
(1:200); antibody (these last four supplied by Santa Cruz
Biotechnology, Inc., CA, USA), were used to detect the
expression of integrin α6, AKT, p-AKT, ERK, and p-ERK
respectively. GAPDH (1:500; Santa Cruz Biotechnology,
Inc., CA, USA) was used as internal control.
Cell proliferation assays
Cell proliferation was determined by MTT assay in ac-
cordance with other studies [11]. Briefly, 2 μg/cm2 of LN
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plate and allowed to solidify at 37°C for two hours. The
other wells were coated with 2 μg/cm2 of fibronectin
(FN) (Sigma, St. Louis, MO, USA) as control. After
washing each well twice with PBS, 8 × 103 cells were in-
cubated in 96-well plates with DMEM containing 10%
FBS at 37°C in 5% CO2 for 48 hours. MTT (10 μl) was
added to each well and four hours later, the media was
aspirated and 100 μl dimethyl sulfoxide (DMSO) was
added. The assay was quantified in a Multimode Micro-
plate Reader-Varioskan Flash (Thermo Electron Corpor-
ation, Waltham, MA, USA) at 490 nm. All experiments
were repeated in at least quadruplicate.
In vitro adhesion assay
LN or FN was coated in 96-well plates according to the
method described above [12]. In total, 8 × 103 cells sus-
pended in DMEM were cultured at 37°C in 5% CO2 for
30 minutes. After being washed with DMEM three times,
acid phosphatase substrate consisting of 0.1 mol/l sodium
acetate buffer (pH 5.5), 0.1% Triton X-100 (10 mmol/L),
and nitrophenylphosphate 100 μl were added to each well.
The cells were cultured at 37°C for two hours, then 1 mol/
L NaOH 10 μl was added to each well to stop the reaction.
The adhesion assay was quantified in a Multimode Micro-
plate Reader-Varioskan Flash (Thermo, Electron Corpor-
ation, Waltham, MA, USA) at 405 nm. All the results were
obtained from at least three independent experiments.
In vitro spreading assay
LN was coated in 96-well plates according to the method
described above. In total, 8 × 103 cells suspended in
DMEM were cultured at 37°C at 5% CO2 for 150 minutes.
Then, a light microscope (×200) was used to determine
the spreading assay. In this experiment, spreading cells
were counted respectively in three distinct visions.
LN invasion assay
The upper part of the Transwell chambers coated with LN
was used as a basement membrane (BM) according to the
way described above. Fibronectin (FN) was used as con-
trol. Cells (1 × 105) suspended in DMEM containing 0.1%
FBS were plated in the upper part to make contact with
the BM. BSA (0.05%) in DMEM with 10% FBS was placed
in the lower chamber, to act as chemoattractants. Cell in-
vasion was determined by crystal violet dissolution assay
after incubation at 37°C in 5% CO2 for 48 hours; the in-
vaded cells were numerated under a light microscope
(×400). In this experiment, invaded cells were counted in
three distinct microscopic fields respectively.
The signal pathways assay
LN or FN was coated in 24-well plates according to the
method described above. Cells (1.5 × 106), serum-starvedfor 48 hours, were allowed to adhere to the LN or FN and
incubated at 37°C in 5% CO2 for two hours. In order to
demonstrate the PI3K/AKT and MAPK/ERK signal path-
ways, which are necessary for the reaction between HCC
cells and LN, PI3K inhibitor LY294002 was used one hour
before HepG2 cells were cultured in plates coated with
2 μg/cm2 of LN. DMSO was used as control. Protein and
mRNA were extracted and analyzed as described in the
western blot assay and real-time quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) assay.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 for
Windows (Chicago, IL, USA). Values are expressed as
the mean ± standard deviation. The student t-test was
used for comparison between groups. P < 0.05 was con-
sidered statistically significant.
Results
The stable transfection of integrin α6-shRNA plasmid dra-
matically down-regulated the expression of integrin α6
As shown in Figure 1, in the western blot assay, com-
pared with the control group, the protein grayscale value
of integrin α6 reduced remarkably in the HepG2-
shRNA-integrin α6 cells (Figure 1A). In the qRT-PCR
assays, compared with the control group, the relative
integrin α6 mRNA reduced remarkably (P < 0.05)
(Figure 1B). About 75% of integrin α6 was from knock-
down by shRNA. The same result can be found in Bel-
7402 cells (P < 0.001).
The results demonstrated that the expression level of
integrin α6 was dramatically down-regulated after stable
transfection at both protein and RNA level with signifi-
cant statistical difference.
Lower integrin α6 expression caused decreased
proliferation of HCC cells on LN
As shown in Figure 2, a lower level of integrin α6 caused
decreased proliferation of HCC cells on LN. This sug-
gested that the proliferation of HCC cells was associated
with the expression level of integrin α6 reacting with LN.
Lower integrin α6 expression caused decreased invasion
potential of HCC cells
To specifically address the importance role of integrin
α6 in the invasion of HCC cells, we performed the
Transwell experiments coated with LN or FN. We found
that cells expressing lower-level integrin α6 showed a
lower invasion potential (Figure 3). A total of 91.0 ± 1.33
HepG2-control shRNA cells crossing LN, compared to
8.67 ± 1.56 in the HepG2-integrin α6 shRNA cells (P <
0.0001) (Figure 3D). Furthermore, the number of
HepG2-control shRNA cells crossing FN (75.0 ± 2.67)
was significantly less than the cells crossing LN (P =
Figure 1 HepG2 and Bel-7402 cells were infected with integrin α6 short hairpin RNA (shRNA) plasmids and control shRNA plasmids
respectively. Stable transfectant clones were picked up by puromycin. Integrin α6 expression levels remarkably reduced. (A) Western blot assays
yielded the expression level of integrin α6 on protein level in HepG2 and Bel-7402 cell lines. (B) The qRT-PCR assays showed the expression level
of integrin α6 on mRNA level in HepG2 and Bel-7402 cell lines. *P < 0.05; ***P < 0.001 compared with control group.
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level expression of integrin α6 caused decreased invasion
potential for HCC cells, and LN can increase invasion
potential of HCC cells with high integrin α6 levels.
Lower integrin α6 expression reduced invasion potential
of HCC cells through the down-regulation of adhesion
ability, spreading ability and secretion of MMPs
It has been mentioned above that adhesion and spreading
is the first step of the model for tumor metastasis reported
by Liotta et al., so we performed adhesion and spreading
assays in vitro. These yielded results showing that theFigure 2 Cells were incubated in 96-well plates coated with laminin (
showed that the lower-level expression of integrin α6 caused decreased pr
the cells incubated on LN, while the cells incubated on FN did not show a
compared with control group.adhesion ability reduced remarkably in the HCC cells
with lower-level expression of integrin α6 (P < 0.0001)
(Figure 4A). On spreading, the results showed that HepG2
cells with lower level of integrin α6 had a lower rate of
spreading (2.4% in the HepG2-shRNA-integrin α6 and
94% in the HepG2) (Figure 4B). The qRT-PCR assay
was used to detect the relative integrin MMP-2 and
MMP-9 levels. Compared with control group, the rela-
tive MMP-2 and MMP-9 mRNA reduced remarkably
(P < 0.01) (Figure 4C, D). Thus, the down-regulation of
MMP-2 and MMP-9 secretion, adhesion and spreading
ability may cause the low invasion potential of HCC cells.LN) or fibronectin (FN) respectively for 48 hours. The MTT assays
oliferation of HCC cells with significant statistical difference (P < 0.05) in
ny statistically significant effect (P > 0.05). *P < 0.05, ****P < 0.0001
Figure 3 Cells were cultured in Transwell chambers with the upper part coated with laminin (LN) or fibronectin (FN) respectively for
48 hours. The invaded cells were numerated under a light microscope (×400). (A) HepG2 infected by control shRNA plasmids invaded LN. (B)
HepG2 cells infected by control shRNA plasmids invaded FN. (C) HepG2 cells infected by integrin α6 shRNA plasmids invaded LN. HepG2 had a
decreased invasion potential after the knockdown of integrin α6 with significant statistical difference (P < 0.0001). It also proved that LN can
increase invasion potential of HepG2 (P < 0.05).
Figure 4 Cells were cultured in 96-well plates coated with laminin (LN) or fibronectin (FN) respectively for 30 minutes and then
cultured with acid phosphatase substrate at 37°C. The reaction was stopped two hours later. (A) The adhesion assays showed that lower-
level integrin α6 reduced the adhesion of HCC cells with significantly statistical difference (P < 0.0001) in the cells incubated with LN, while the
cells incubated with FN did not show any significant effect (P > 0.05). (B) Cells cultured in 96-well plates were coated with LN for 150 minutes.
The spreading cells were numerated under a light microscope (×200). HepG2 cells with lower level of integrin α6 had a lower spreading rate.
(C) The qRT-PCR assay showed that MMP-2 expression reduced significantly at mRNA level (P < 0.01). (D) The qRT-PCR assay showed that MMP-9
expression reduced significantly at RNA level (P < 0.01). *P < 0.05, **P < 0.01, ****P < 0.0001 compared with control.
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of PI3K/AKT and MAPK/ERK signal pathways
As shown in Figure 5, compared with the control group,
the protein grayscale value of p-ERK, p-AKT was dra-
matically reduced in HepG2 cells transfected with integ-
rin α6 shRNA plasmids compared with control shRNA
plasmids (Figure 5A, B). As revealed in Figure 5C,
LY294002 decreased both the expression of p-ERK and
p-AKT, but had no influence on the expression of ERK
and AKT. The proliferation of HepG2 cells was remark-
ably decreased after being inhibited by PI3K (P < 0.05)
(Figure 5D). In Transwell assays, 38.33 ± 3.78 cells
crossed LN in the HepG2/LY294002 group, while 64.0 ±
2.67 cells in the HepG2/DMSO group and 72.33 ± 3.11
cells in HepG2 group (P < 0.05) (Figure 5E) crossed LN.
These results demonstrated that the reacting of integrin
α6 with LN induced the hyperactivation of PI3K/AKT
and MAPK/ERK signal pathways.Figure 5 Expression levels determination of PI3K/AKT and MAPK/ERK
lower in HepG2 and Bel-7402 cells transfected with integrin α6 short hairpi
unchanged. Cells transfected with control shRNA plasmids show no differe
expression of p-AKT was lower in HepG2 and Bel-7402 cells transfected wit
remained unchanged. Cells transfected with control shRNA plasmids show
showed that PI3K inhibitor LY294002 reduced the expression of both p-AK
cells cultured with LY294002 was dramatically reduced (P < 0.05). (E) Transw
with LY294002 was dramatically reduced (P < 0.05). *P < 0.05 compared witDiscussion
Metastatic recurrence is the main obstacle to the im-
provement of treatment efficacy for HCC [13], and het-
erodimeric transmembrane protein generated by integrin
α6 subunits is suggested to be associated with metastasis
potential of HCC. In this study, we used LN, the import-
ant structural component of ECM and integrin α6 lig-
and, as a model molecule and applied several assays to
determine the importance of integrin α6 in the metasta-
sis of HCC cells. In order to make the results more ob-
jective, the integrin α6 shRNA was used to silence the
expression of integrin α6 of two HCC cell lines at RNA
level. Western blot and qRT-PCR detection showed that
over 75% of integrin α6 expression in HCC cells was
through knockdown by shRNA.
Tumor metastasis is a multi-step process involving
various molecules, pathways and organs. This process
mainly includes the following steps before invasion to. (A) Western blot assay revealed the expression level of p-ERK was
n RNA (shRNA) plasmids, while the expression of ERK remained
nce on p-ERK and ERK expression. (B) Western blot assay revealed the
h integrin α6 shRNA plasmids, while the expression level of AKT
no difference in p-AKT and AKT expression. (C) Western blot assay
T and p-ERK. (D) MTT assay showed that the proliferation of HepG2
ell assay showed that the invasion potential of HepG2 cells cultured
h control.
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http://www.eurjmedres.com/content/18/1/52form micrometastases in the metastatic site: the detach-
ment of tumor cells from a primary tumor, invasion
through the stromal tissues, intravasation into the
blood/lymph vessels, arrest in capillary bed followed by
extravasation and local crawling [14].
Based on the results of our assays, lower-level integ-
rinα6 expression down-regulated the secretion of matrix
metalloproteinases (MMPs), the adhesion force between
HCC cells and LN, the spreading ability on the LN, as
well as the invasion potential of HCC cells. p-ERK and
p-AKT were reduced by shRNA targeting integrin α6
and PI3K inhibitor LY294002. LN could stimulate the
MMPs secreted by HCC and thus was associated with a
more metastatic phenotype of HCC cells [15]. The phos-
phorylation level of ERK and AKT (p-ERK and p-AKT),
which has been reported to be increased after combining
integrin α6 with LN [16,17], is associated with a low sur-
vival rate for HCC patients [17]. Furthermore, influen-
cing factors increase the secretion of MMP-9 through
the activation of the MAPK/ERK signal pathway, which
is conducive with HCC metastasis [18]. The same results
have been found in the PI3K/AKT signal by Chen et al.
[19].
A model for tumor metastasis reported by Liotta et al.
[20] in the early 1980s contributes in large part to the
metastatic process. The model mentions that there are
three stages for the complicated interactions between
tumor cells and ECM: the adhesion of tumor cells to the
ECM, secretion of proteolytic enzymes, such as MMPs,
directly by the tumor cells or indirectly by the host cells
as a response to the presence of tumor cells, and finally,
cell movement by chemotaxis or haptotaxis. Although
most integrin family members recognize more than one
ECM protein, integrin α6 is a ligand with specificity for
LN [21,22]. The signal pathways, MAPK/ERK and PI3K/
AKT have been proved to be necessary for HCC metas-
tasis [19,23]. Thus, we can hypothesize that the combin-
ation of integrin α6 with LN could influence the HCC
metastasis by affecting cell adhesion and migration, and
reduced expression level of integrin α6 may cause low
potential of HCC metastasis through the activation of
MAPK/ERK and PI3K/AKT signal pathways. There also
exist cross-talk between the two signaling pathways acti-
vated by LN [18,19]. Integrin α6 contributes to the regu-
lation of interaction between HCC cells and LN through
PI3K/AKT and MAPK/ERK signaling pathways which
are shown to be essential for the metastasis of HCC [6].
Conclusions
Down-regulation of integrin α6 could decrease the po-
tential of HCC metastasis through reducing the inter-
action between HCC and LN. This study showed that
over-expression of integrin α6 in HCC is a strong indi-
cator for more aggressive tumors and poorer clinicaloutcome. All the currently available therapies for HCC
are mainly oriented towards removing or destroying the
tumors, whereas few therapies aim at blocking the
process of HCC metastasis [24]. This study would help
us to understand the metastatic process of HCC better
and develop targeted molecular therapy to improve pa-
tients’ survival.
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